← Back to all trials
Recruiting
NCT05658822
Digestive Dysmotility in Mitochondrial Neurogastrointestinal Encephalomyopathy
Conditions: MNGIE, Dysmotility
Sex: All
Enrollment: 6
Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Location: Spain
Summary
Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is an ultra-rare mitochondrial disease caused by mutations of the gen that codifies the enzyme thymidine phosphorylase The genetic defect results in systemic accumulation of the nucleosides thymidine and deoxyuridine.
Clinically MNGIE is characterized by a combination of gastrointestinal and neurological manifestations, including severe gastrointestinal dysmotility, cachexia, ptosis, external ophthalmoplegia and sensorimotor neuropathy.
Gastrointestinal symptoms are the most frequent first manifestation of the disease, and include early satiety, nausea, dysphagia, postprandial emesis, abdominal pain, abdominal distention, and diarrhea.
The disease is relentlessly progressive and the cause of death is primarily related to digestive dysmotility.
However, the specific motor dysfunctions that produce the symptoms, i.e., the underlying mechanisms, remain uncertain.
Eligibility Criteria
Inclusion Criteria:diagnosis of MNGIE disease established by thymidine phosphorylase activity and mitochondrial mutation analysis.
Source: ClinicalTrials.gov (NCT05658822). StuddyBuddy aggregates publicly available trial information.